Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 645 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Process-level Clear all
Completed Phase 1 Interventional

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

NCT00952237
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis), Leukemia
Interventions
GM-CSF, IL-2
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting Not applicable Interventional

OurSleepKit To Support CPAP Adherence

NCT06621511
View directory record Official record
Conditions
Obstructive Sleep Apnea, CPAP Treatment, Treatment Adherence
Interventions
OurSleepKit
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Not applicable Interventional Results available

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 44 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting Not applicable Interventional

Adjunctive Motivational Alcohol Intervention to Prevent IPV

NCT05287711
View directory record Official record
Conditions
Alcohol Use and Intimate Partner Violence
Interventions
Motivational Enhancement Therapy, Alcohol Education Control, Treatment as Usual, Strength at Home
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

NCT01339572
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Multiple Myeloma
Interventions
Plerixafor, Filgrastim
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

NCT01203722
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Fludarabine, Cytoxan, Total Body Irradiation, Allogeneic Blood or Marrow Transplant, Peripheral Blood Stem Cell Transplant, Mycophenolate Mofetil, Sirolimus, Tacrolimus
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional

Influence of Public Parks on Physical Activity Levels of Diverse Communities

NCT00693901
View directory record Official record
Conditions
Physical Activity
Interventions
Community-based participatory research (CBPR), Director-only
Behavioral
Lead sponsor
RAND
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional

TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry

NCT07088770
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Substance Abuse Disorder
Interventions
Community Coalition CLS Workgroup/Network of Providers, Tech-mediated Training and Service Delivery, Multidisciplinary Implementation Team with Champion, Tech-mediated Peer Navigation Enhanced Case management (NCM)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kingston, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Not yet recruiting Phase 2 Interventional

CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

NCT07808112
View directory record Official record
Conditions
Graft -Versus-host-disease
Interventions
Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil (MMF), Axatilimab
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interventions to Help More Low-income Smokers Quit

NCT04311983
View directory record Official record
Conditions
Tobacco Use Cessation, Smoking Behaviors, Health Disparity
Interventions
Tobacco Quitline, Smoke Free Home
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
1,973 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

NCT00043979
View directory record Official record
Conditions
Sarcoma
Interventions
F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, melphalan, prednisone, sirolimus, tacrolimus, vincristine sulfate, peripheral blood stem cell transplantation, Filgrastim, Peripheral Blood Stem Cell donation
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 20, 2026, 4:48 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

NCT02663297
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions
ATLCAR.CD30 cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

NCT00309842
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional

Optimal Performance of RFA of the Nerves Supplying the Posterior Sacroiliac Joint Complex.

NCT02808962
View directory record Official record
Conditions
Osteoarthritis Nos, of Sacroiliac Joint
Interventions
Cooled RFA of sacral lateral branches
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

NCT02955550
View directory record Official record
Conditions
Multiple Myeloma
Interventions
rhIL-2, PNK-007
Drug · Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Not applicable Interventional

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

NCT03618979
View directory record Official record
Conditions
Low Back Pain
Interventions
PPP treatment, PRP treatment, PRP and PL Combo treatment
Biological
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Broomfield, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional

Repisodic & Skilled Nursing Facility Preferred Provider Networks

NCT04263779
View directory record Official record
Conditions
Skilled Nursing Facilities, Behavioral Economics
Interventions
Order of Options, Default Option
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
5,581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional Results available

Effects of Exercise in Combination With Epoetin Alfa

NCT00577096
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
Drug · Behavioral · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 20, 2026, 4:48 AM EDT
Not listed No phase listed Observational

Psychosocial Determinants of Medication Adherence in Hypertensive African Americans

NCT00195182
View directory record Official record
Conditions
Hypertension
Interventions
Self affirmation and positive affect induction vs. control
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

NCT03677596
View directory record Official record
Conditions
Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA
Interventions
inotuzumab ozogamicin-dose level 2, Inotuzumab ozogamicin-dose level 1
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

N99-02: Melphalan and Buthionine Sulfoximine

NCT00005835
View directory record Official record
Conditions
Neuroblastoma
Interventions
buthionine sulfoximine, melphalan, Peripheral blood stem cell infusion, Filgrastim
Drug · Procedure · Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
Up to 30 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

NCT06450925
View directory record Official record
Conditions
Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency
Interventions
Vitamin A, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Tampa, Florida • Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Rejuvenated RBC and VO2 Max in Healthy Subjects

NCT03089047
View directory record Official record
Conditions
Erythrocyte Transfusion
Interventions
Transfusion of rejuvenated and washed autolgous RBCs, Transfusion of washed autolgous RBCs
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 20, 2026, 4:48 AM EDT